Novo Nordisk, a global healthcare company, agreed to acquire Corvidia Therapeutics, an AstraZeneca spin-off and a clinical-stage company focused on the research, development and commercialization of transformative therapies for cardio-renal diseases, from Sofinnova Partners, a European life sciences venture capital firm based in Paris, for $2.1bn. “This milestone demonstrates the strength of our cornerstone strategy of backing extraordinary entrepreneurs with whom we have long-standing relationships. Moreover, it exemplifies the resilience of our business of developing game-changing therapies that will impact patients’ lives, while consistently generating outsized venture returns for investors, despite the challenges of the current global crisis,” Graziano Seghezzi, Sofinnova Partners Managing Partner.